Let's Get Started

biotech

Biotechnology Value Fund is Buying Xoma Corp (NASDAQ:XOMA) Shares

Biotechnology Value Fund is Buying Xoma Corp (NASDAQ:XOMA) Shares

Feb 21, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Xoma Corp (NASDAQ:XOMA) reported that Biotechnology Value Fund L P has picked up 695,726 of common stock as of 2017-02-21.

The acquisition brings the aggregate amount owned by Biotechnology Value Fund L P to a total of 695,726 representing a 9.2% stake in the company.

For those not familiar with the company, XOMA Corporation (NASDAQ:XOMA) is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.

A glance at Xoma Corp (NASDAQ:XOMA)’s key stats reveals a current market capitalization of 39.56 million based on 7.52 million shares outstanding and a price at last close of $5.16 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2013-08-19, Baker picked up 21,410 at a purchase price of $3.62. This brings their total holding to 510,449 as of the date of the filing.

On the sell side, the most recent transaction saw Neal unload 95 shares at a sale price of $4.50. This brings their total holding to 20,471.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Xoma Corp (NASDAQ:XOMA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
1globe Capital Llc. Picked Up Exelixis Inc. (NASDAQ:EXEL) Shares

1globe Capital Llc. Picked Up Exelixis Inc. (NASDAQ:EXEL) Shares

Feb 15, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Exelixis Inc. (NASDAQ:EXEL) reported that 1globe Capital Llc. has picked up 5,437,285 of common stock as of 2017-02-15.

The acquisition brings the aggregate amount owned by 1globe Capital Llc. to a total of 5,437,285 representing a 1.9% stake in the company.

For those not familiar with the company, Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

A glance at Exelixis Inc. (NASDAQ:EXEL)’s key stats reveals a current market capitalization of 6.08 billion based on 286.46 million shares outstanding and a price at last close of $22.02 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-05-11, Willsey picked up 20,000 at a purchase price of $4.95. This brings their total holding to 568,273 as of the date of the filing.

On the sell side, the most recent transaction saw Lamb unload 70,000 shares at a sale price of $18.65. This brings their total holding to 73,600.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Exelixis Inc. (NASDAQ:EXEL) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
Vaccinogen Inc. (OTCMKTS:VGEN) is Attracting Smart Money

Vaccinogen Inc. (OTCMKTS:VGEN) is Attracting Smart Money

Feb 13, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vaccinogen Inc. (OTCMKTS:VGEN) reported that Mpm Bioventures Iii L.p. has picked up 134,452 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by Mpm Bioventures Iii L.p. to a total of 134,452 representing a 0.4% stake in the company.

For those not familiar with the company, Vaccinogen, Inc. is a biotechnology company. The Company is the developer of OncoVAX. OncoVAX is an active specific immunotherapy (ASI) that uses the patient’s own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. OncoVAX is a patient specific immunotherapy for stage II colon cancer and its technology may have application in other tumor types, such as melanoma and renal cell carcinoma. The OncoVAX patient-specific vaccine consists of sterile, metabolically active, irradiated and non-tumorigenic autologous cancer cells, with or without fresh frozen Bacillus Calmette-Guerin (BCG) bacteria as an adjuvant. The Company has completed a Phase IIIa study of OncoVAX.

A glance at Vaccinogen Inc. (OTCMKTS:VGEN)’s key stats reveals a current market capitalization of 7.24 million based on 37.32 million shares outstanding and a price at last close of 0.169 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-12-26, Halldin picked up 934,580 at a purchase price of $5.50. This brings their total holding to 934,580 as of the date of the filing.

On the sell side, the most recent transaction saw Hanna unload 1,000 shares at a sale price of $3.61. This brings their total holding to 224,587.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vaccinogen Inc (OTCMKTS:VGEN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
Primecap Management Co/ca/ Picked Up Accuray Inc. (NASDAQ:ARAY) Shares

Primecap Management Co/ca/ Picked Up Accuray Inc. (NASDAQ:ARAY) Shares

Feb 13, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Accuray Inc. (NASDAQ:ARAY) reported that Primecap Management Co/ca/ has picked up 5,513,300 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by Primecap Management Co/ca/ to a total of 5,513,300 representing a 6.75% stake in the company.

For those not familiar with the company, Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

A glance at Accuray Inc. (NASDAQ:ARAY)’s key stats reveals a current market capitalization of 455.94 million based on 82.90 million shares outstanding and a price at last close of $5.50 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-11-9, Levine picked up 50,000 at a purchase price of $7.12. This brings their total holding to 1,115,830 as of the date of the filing.

On the sell side, the most recent transaction saw Nouri unload 957 shares at a sale price of $6.80. This brings their total holding to 65,547.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Accuray Inc. (NASDAQ:ARAY) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
OrbiMed Advisors is Buying Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Shares

OrbiMed Advisors is Buying Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Shares

Feb 13, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reported that OrbiMed Advisors has picked up 2,524,000 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by OrbiMed Advisors to a total of 2,524,000 representing a 1.73% stake in the company.

For those not familiar with the company, Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.

A glance at Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)’s key stats reveals a current market capitalization of 2.41 billion based on 130.86 million shares outstanding and a price at last close of $16.42 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2011-11-02, Hecht picked up 50,000 at a purchase price of $11.65. This brings their total holding to 72,803 as of the date of the filing.

On the sell side, the most recent transaction saw Hecht unload 32,994 shares at a sale price of $15.50. This brings their total holding to 4,670,322.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
Guess Who Picked Up Integra Lifesciences Holdings Corp. (NASDAQ:IART) Shares

Guess Who Picked Up Integra Lifesciences Holdings Corp. (NASDAQ:IART) Shares

Feb 13, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Integra Lifesciences Holdings Corp. (NASDAQ:IART) reported that Caruso Richard E. has picked up 6,201,027 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by Caruso Richard E. to a total of 6,201,027 representing a 16.57% stake in the company.

For those not familiar with the company, Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.

A glance at Integra Lifesciences Holdings Corp (NASDAQ:IART)’s key stats reveals a current market capitalization of 3.20 billion based on 74.77 million shares outstanding and a price at last close of $42.90 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2011-11-02, Caruso picked up 2,000 at a purchase price of $28.46. This brings their total holding to 2,000 as of the date of the filing.

On the sell side, the most recent transaction saw Arduini unload 20,000 shares at a sale price of $80.02. This brings their total holding to 25,593.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Integra Lifesciences Holdings Corp. (NASDAQ:IART) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
Columbia Wanger Asset Management is Buying Celldex Therapeutics Inc. (NASDAQ:CLDX) Shares

Columbia Wanger Asset Management is Buying Celldex Therapeutics Inc. (NASDAQ:CLDX) Shares

Feb 10, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Celldex Therapeutics Inc. (NASDAQ:CLDX) reported that Columbia Wanger Asset Management Llc. has picked up 6,195,855 of common stock as of 2017-02-10.

The acquisition brings the aggregate amount owned by Columbia Wanger Asset Management Llc. to a total of 6,195,855 representing a 5.1% stake in the company.

For those not familiar with the company, Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

A glance at Celldex Therapeutics Inc. (NASDAQ:CLDX)’s key stats reveals a current market capitalization of 416.17 million based on 122.28 million shares outstanding and a price at last close of $3.45 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-08-25, Ellberger picked up 5,000 at a purchase price of $14.00. This brings their total holding to 53,500 as of the date of the filing.

On the sell side, the most recent transaction saw Catlin unload 25,000 shares at a sale price of $18.00. This brings their total holding to 35,109.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Celldex Therapeutics Inc. (NASDAQ:CLDX) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
Here’s Who Just Picked Up Natera Inc. (NASDAQ:NTRA) Shares

Here’s Who Just Picked Up Natera Inc. (NASDAQ:NTRA) Shares

Feb 9, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Natera Inc. (NASDAQ:NTRA) reported that Claremont Creek Ventures L P. has picked up 7,020,856 of common stock as of 2017-02-09.

The acquisition brings the aggregate amount owned by Claremont Creek Ventures L P. to a total of 7,020,856 representing a 13.4% stake in the company.

For those not familiar with the company, Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).

A glance at Natera Inc. (NASDAQ:NTRA)’s key stats reveals a current market capitalization of 490.34 million based on 52.38 million shares outstanding and a price at last close of $9.31 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-06-19, Steuart picked up 66,621 at a purchase price of $11.94. This brings their total holding to 83,752 as of the date of the filing.

On the sell side, the most recent transaction saw Rosenman unload 1,850 shares at a sale price of $8.95. This brings their total holding to 34,755.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Natera Inc. (NASDAQ:NTRA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
Sramowicz Steven is Buying Rennova Health Inc. (NASDAQ:RNVA) Shares

Sramowicz Steven is Buying Rennova Health Inc. (NASDAQ:RNVA) Shares

Feb 9, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Rennova Health Inc. (NASDAQ:RNVA) reported that Sramowicz Steven has picked up 3,855,659 of common stock as of 2017-02-01.

The acquisition brings the aggregate amount owned by Sramowicz Steven to a total of 3,855,659 representing a 23.0% stake in the company.

For those not familiar with the company, Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.

A glance at Rennova Health Inc. (NASDAQ:RNVA)’s key stats reveals a current market capitalization of 4.86 million based on 84.01 million shares outstanding and a price at last close of $0.070 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-07-14, Diamantis picked up 333,333 at a purchase price of $0.44. This brings their total holding to 681,526  as of the date of the filing.

On the sell side, the most recent transaction saw Alcatel-Lucent unload 7,843 shares at a sale price of $4.60. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Rennova Health Inc. (NASDAQ:RNVA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more